ADAP Advocacy Exposes Hospital CEO Pay Surge Under 340B Drug Pricing Program

New infographics from ADAP Advocacy reveal that the 340B Drug Pricing Program, intended to help poor patients, is funding excessive hospital CEO compensation as the program grows to $66 billion.

Chicago Metrowire Staff
Healthcare
ADAP Advocacy Exposes Hospital CEO Pay Surge Under 340B Drug Pricing Program

ADAP Advocacy today, as part of its 340B Project, published infographics highlighting excessive executive compensation packages among hospital CEOs and the impact on patients. The infographics complement the recently released commercial and are part of the ongoing 340B national advocacy campaign, 'Is the 340B Drug Pricing Program the Next 'Too Big to Fail'?'

The '340B Too Big to Fail – Executive Compensation – Part 1' infographic focuses on the CEO pay gap relative to frontline nurses and on how the 340B Drug Pricing Program was designed to help poor patients access healthcare services. Yet, despite this program growing to $66 billion, manufacturer rebates are being used to fund excessive compensation for hospital CEOs.

The '340B Too Big to Fail – Executive Compensation – Part 2' infographic showcases how CEO pay has grown exponentially after hospital covered entities became eligible to participate in the program. The 340B Program wasn't designed to pad the pockets of these healthcare executives.

The two-part infographic series can be downloaded online here: https://www.adapadvocacy.org/publications.html#i.

Blockchain Registration

QR Code for Blockchain Registration